UroGen Pharma (URGN) Tax Provisions (2020 - 2026)
UroGen Pharma's (URGN) quarterly Tax Provisions came in at -$4.8 million in Q1 2026, down 1317.35% YoY from $392000.0 in Q1 2025, and up 86.61% on a QoQ basis from -$35.6 million in Q4 2025.
UroGen Pharma (URGN) Tax Provisions (2020 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 7 years of Tax Provisions data on file, last reported at -$4.8 million in Q1 2026.
- Quarterly Tax Provisions fell 1317.35% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.4 million (down 43.48% YoY) and the FY2025 annual result came in at -$35.3 million, down 23.68% from the prior year.
- Tax Provisions climbed to -$4.8 million in Q1 2026, from -$35.6 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $1.0 million in Q2 2025 to a low of -$35.6 million in Q4 2025.
- A 5-year average of -$6.8 million and a median of $32000.0 in 2022 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2025 — Tax Provisions surged 2571.05% — and 2026, when it plunged 1317.35%.
- Tracing URGN's Tax Provisions over 5 years: stood at -$25.9 million in 2022, then climbed by 12.47% to -$22.7 million in 2023, then slipped by 26.59% to -$28.7 million in 2024, then slipped by 24.12% to -$35.6 million in 2025, then soared by 86.61% to -$4.8 million in 2026.
- The last three Tax Provisions figures came in at -$4.8 million (Q1 2026), -$35.6 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 5.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.63 Mn |
| Mar 31, 2026 | -4.77 Mn |
| Dec 31, 2025 | -35.64 Mn |
| Sep 30, 2025 | -1.05 Mn |
| Jun 30, 2025 | 1.02 Mn |
| Mar 31, 2025 | 392,000.00 |
| Dec 31, 2024 | -28.71 Mn |
| Sep 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Mar 31, 2024 | 54,000.00 |
| Dec 31, 2023 | -22.68 Mn |
| Sep 30, 2023 | -9,000.00 |
| Jun 30, 2023 | 54,000.00 |
| Mar 31, 2023 | 21,000.00 |
| Dec 31, 2022 | -25.91 Mn |
| Sep 30, 2022 | 709,000.00 |
| Jun 30, 2022 | 32,000.00 |
| Mar 31, 2022 | 325,000.00 |
| Dec 31, 2021 | -25.47 Mn |
| Jun 30, 2021 | 312,000.00 |